David Steinberg

Chief Business Officer

2024

Advancements in AI and drug discovery are creating more candidate drugs than the industry can progress because of the high cost and time of clinical trials. Recognizing that this development bottleneck may ultimately limit the number of new medicines that can reach patients, Formation Bio, founded in 2016 as TrialSpark Inc., has built technology platforms, processes, and capabilities to accelerate all aspects of drug development and clinical trials. Formation Bio partners, acquires, or in-licenses drugs from pharma companies, research organizations, and biotechs to develop programs past clinical proof of concept and beyond, ultimately helping to bring new medicines to patients. The company is backed by investors across pharma and tech, including a16z, Sequoia, Sanofi, Thrive Capital, Sam Altman, John Doerr, Spark Capital, SV Angel Growth, and others.

Board Member, Founding CEO

2022 - 2024

Chairman, Founding CEO

2021 - 2024

Board Member

2021 - 2024

Chairman, Founding CEO

2020 - 2024

Be Biopharma (www.be.bio) is a leader in developing B cells as medicines, treating disease with the human body’s native protein factories. We precisely engineer B cells to harness their intrinsic drug-like properties – remarkable protein production, selective tissue targeting, and fine control of their cellular environment – to forge a new category of cell therapy. These medicines are designed to be durable, re-dosable and administered without toxic conditioning, creating new avenues to halt or reverse severe diseases like cancer, autoimmune conditions, and enzyme deficiency. Founded by Longwood Fund and B cell engineering pioneers David Rawlings, MD, and Richard James, PhD, Be Biopharma is re-imagining medicine based on the power of B cell therapy

General Partner

2019 - 2024

Venture Partner

2018 - 2019

Board Member

2020 - 2023

Founding CEO, former Chairman

2019 - 2021

Pyxis Oncology (NASDAQ:PYXS) is developing therapeutics to promote the body's immune response to cancer, based on new insights into the tumor microenvironment. www.pyxisoncology.com

Co-Founder

2017 - 2020

Targeting the biology of aging to prevent or treat aging-related diseases

Founding CEO

2016 - 2018

Vor Biopharma (NASDAQ:VOR) is focused on developing technologies that can enable selective targeting of cancer cells without impacting normal cells.